Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Everyday Health on MSN
C3G/IC-MPGN progression: Can new C3 inhibitors stop the path to dialysis?
For years, patients with C3G and IC-MPGN had few options to stop the progression toward kidney failure. Now a new class of FDA-approved C3 inhibitors that targets the root of the complement system can ...
Dr Mark Kris highlights a recent study on osimertinib in NSCLC and outlines the best approaches for treatment beyond progression.
Lower eGFR and higher urinary protein-to-creatinine ratio were associated with greater risks for cognitive impairment across the chronic kidney disease spectrum, according to study data published in ...
Gut dysbiosis caused by a high-fat diet can allow bacteria to move from the gut to the brain in mice, according to a new ...
Community programs like Go for Bold improve health, but lasting, equitable gains require complementary structural food policies—including taxes, reformulation, and labeling—to shift environments and ...
Objective: To obtain the derived parameter left atrial stiffness index (LASI) using two-dimensional speckle tracking imaging (2D-STI) and evaluate the diagnostic value o ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results